Brazil’s competition watchdog announced the start of an inquiry into an alleged cartel within public drug acquisition processes, including providers of antidepressants, painkillers, sedatives, anticoagulants and other therapeutic drugs.
The investigation will focus on 15 companies, accused of establishing communication channels to coordinate their prices and gain advantage in public contract contests, restricting competition within the process. Company executives would previously agree on the winner and the amounts bid for each contest, among other violations of competition law.
The case, brought to light through intercepted telephone conversations, will focus on the companies’ actions between 2007 and 2011. The companies will be formally notified of the proceedings and invited to present their defence.
Full content: CADE
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile’s Acquisition of Ka’ena Corporation Receives FCC Approval
Apr 26, 2024 by
CPI
UK Regulator Announces Two New Senior Executive Appointments
Apr 26, 2024 by
CPI
Paramount Global and Skydance Media Near Merger Deal, Eyeing CEO Change
Apr 26, 2024 by
CPI
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI